- Brown P.D.
- Gondi V.
- Pugh S.
- et al.
Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: Phase III trial NRG oncology CC001.
J Clin Oncol. 2020; 38: 1019-1029- Vatner R.E.
- Niemierko A.
- Misra M.
- et al.
Endocrine deficiency as a function of radiation dose to the hypothalamus and pituitary in pediatric and young adult patients with brain tumors.
J Clin Oncol. 2018; 36: 2854-2862- Huynh-Le M.P.
- Tibbs M.D.
- Karunamuni R.
- et al.
Microstructural injury to corpus callosum and intrahemispheric white matter tracts correlate with attention and processing speed decline after brain radiation.
Int J Radiat Oncol Biol Phys. 2021; 110: 337-347- Combs S.E.
- Schulz-Ertner D.
- Herfarth K.K.
- et al.
Advances in radio-oncology. From precision radiotherapy with photons to ion therapy with protons and carbon ions.
Chirurg. 2006; 77: 1126-1132- Paganetti H.
- van Luijk P.
Biological considerations when comparing proton therapy with photon therapy.
Semin Radiat Oncol. 2013; 23: 77-87- Ostrom Q.T.
- Gittleman H.
- Truitt G.
- et al.
CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015.
Neuro Oncol. 2018; 20: iv1-iv86- Tunthanathip T.
- Ratanalert S.
- Sae-Heng S.
- et al.
Prognostic factors and nomogram predicting survival in diffuse astrocytoma.
J Neurosci Rural Pract. 2020; 11: 135-143- van den Bent M.J.
- Afra D.
- de Witte O.
- et al.
Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial.
Lancet. 2005; 366 (): 985-990- Shaw E.G.
- Berkey B.
- Coons S.W.
Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: Results of a prospective clinical trial.
J Neurosurg. 2008; 109: 835-841- Buckner J.C.
- Shaw E.G.
- Pugh S.L.
- et al.
Radiation plus Procarbazine, CCNU, and vincristine in low-grade Glioma.
N Engl J Med. 2016; 374: 1344-1355- Dennis E.R.
- Bussiere M.R.
- Niemierko A.
- et al.
A comparison of critical structure dose and toxicity risks in patients with low grade gliomas treated with IMRT versus proton radiation therapy.
Technol Cancer Res Treat. 2013; 12: 1-9- Eekers D.B.P.
- Roelofs E.
- Cubillos-Mesías M.
- et al.
Intensity-modulated proton therapy decreases dose to organs at risk in low-grade glioma patients: results of a multicentric in silico ROCOCO trial.
Acta Oncol. 2019; 58: 57-65- Hauswald H.
- Rieken S.
- Ecker S.
- et al.
First experiences in treatment of low-grade glioma grade I and II with proton therapy.
Radiat Oncol. 2012; 7: 189- Tabrizi S.
- Yeap B.Y.
- Sherman J.C.
- et al.
Long-term outcomes and late adverse effects of a prospective study on proton radiotherapy for patients with low-grade glioma.
Radiother Oncol. 2019; 137: 95-101Molecular markers in low-grade glioma-toward tumor reclassification.
Semin Radiat Oncol. 2015; 25: 155-163- Eckel-Passow J.E.
- Lachance D.H.
- Molinaro A.M.
- et al.
Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors.
N Engl J Med. 2015; 372: 2499-3250- Baumert B.G.
- Hegi M.E.
- van den Bent M.J.
- et al.
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Lancet Oncol. 2016; 17: 1521-2153- Cairncross G.
- Wang M.
- Shaw E.
- et al.
Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.
J Clin Oncol. 2013; 31: 337-343- Trifiletti D.M.
- Brown P.D.
Cognitive outcomes in patients with low-grade glioma.
Neuro Oncol. 2021; 23: 709-710- Perry J.R.
- Laperriere N.
- O'Callaghan C.J.
- et al.
Short-course radiation plus temozolomide in elderly patients with glioblastoma.
N Engl J Med. 2017; 376: 1027-1037- Stupp R.
- Hegi M.E.
- Mason W.P.
- et al.
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Lancet Oncol. 2009; 10: 459-466- Gilbert M.R.
- Wang M.
- Aldape K.D.
- et al.
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
J Clin Oncol. 2013; 31: 4085-4091- Brown P.D.
- Chung C.
- Liu D.D.
- et al.
A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma.
Neuro Oncol. 2021; 23: 1337-1347- Fitzek M.M.
- Thornton A.F.
- Rabinov J.D.
- et al.
Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a phase II prospective trial.
J Neurosurg. 1999; 91: 251-260- Hingorani M.
- Colley W.P.
- Dixit S.
- et al.
Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or hope for the future?.
Br J Radiol. 2012; 85: e770-e781- Grossman S.A.
- Ye X.
- Lesser G.
- et al.
Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide.
Clin Cancer Res. 2011; 17: 5473-5480- Mohan R.
- Liu A.Y.
- Brown P.D.
- et al.
Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons.
Neuro Oncol. 2021; 23: 284-294- Seystahl K.
- Wick W.
- Weller M.
Therapeutic options in recurrent glioblastoma--An update.
Crit Rev Oncol Hematol. 2016; 99: 389-408- Saeed A.M.
- Khairnar R.
- Sharma A.M.
- et al.
Clinical outcomes in patients with recurrent glioblastoma treated with proton beam therapy reirradiation: analysis of the multi-institutional proton collaborative group registry.
Adv Radiat Oncol. 2020; 5: 978-983- Scartoni D.
- Amelio D.
- Palumbo P.
- et al.
Proton therapy re-irradiation preserves health-related quality of life in large recurrent glioblastoma.
J Cancer Res Clin Oncol. 2020; 146: 1615-1622- Rogers L.
- Zhang P.
- Vogelbaum M.A.
- et al.
Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539.
J Neurosurg. 2018; 129 (): 35-47- Baumert B.G.
- Norton I.A.
- Lomax A.J.
- et al.
Dose conformation of intensity-modulated stereotactic photon beams, proton beams, and intensity-modulated proton beams for intracranial lesions.
Int J Radiat Oncol Biol Phys. 2004; 60: 1314-1324- Bolsi A.
- Fogliata A.
- Cozzi L.
Radiotherapy of small intracranial tumours with different advanced techniques using photon and proton beams: a treatment planning study.
Radiother Oncol. 2003; 68: 1-14- Florijn M.A.
- Sharfo A.W.M.
- Wiggenraad R.G.J.
- et al.
Lower doses to hippocampi and other brain structures for skull-base meningiomas with intensity modulated proton therapy compared to photon therapy.
Radiother Oncol. 2020; 142: 147-153- Miralbell R.
- Cella L.
- Weber D.
- et al.
Optimizing radiotherapy of orbital and paraorbital tumors: intensity-modulated X-ray beams vs. intensity-modulated proton beams.
Int J Radiat Oncol Biol Phys. 2000; 47: 1111-1119- Arvold N.D.
- Niemierko A.
- Broussard G.P.
- et al.
Projected second tumor risk and dose to neurocognitive structures after proton versus photon radiotherapy for benign meningioma.
Int J Radiat Oncol Biol Phys. 2012; 83: e495-e500- Chung C.S.
- Yock T.I.
- Nelson K.
- et al.
Incidence of second malignancies among patients treated with proton versus photon radiation.
Int J Radiat Oncol Biol Phys. 2013; 87: 46-52- Sato H.
- Mizumoto M.
- Okumura T.
- et al.
Long-term outcomes of patients with unresectable benign meningioma treated with proton beam therapy.
J Radiat Res. 2021; 62: 427-437- Murray F.R.
- Snider J.W.
- Bolsi A.
- et al.
Long-term clinical outcomes of pencil beam scanning proton therapy for benign and non-benign intracranial meningiomas.
Int J Radiat Oncol Biol Phys. 2017; 99: 1190-1198- Rogers L.
- Barani I.
- Chamberlain M.
- et al.
Meningiomas: knowledge base, treatment outcomes, and uncertainties: a RANO review.
J Neurosurg. 2015; 122: 4-23- Imber B.S.
- Neal B.
- Casey D.L.
- et al.
Clinical outcomes of recurrent intracranial meningiomas treated with proton beam reirradiation.
Int J Part Ther. 2019; 5: 11-22- Zhang Y.Y.
- Huo W.L.
- Goldberg S.I.
- et al.
Brain-specific relative biological effectiveness of protons based on long-term outcome of patients with nasopharyngeal carcinoma.
Int J Radiat Oncol Biol Phys. 2021; 110: 984-992Relative survival of childhood and adult medulloblastomas and primitive neuroectodermal tumors (PNETs).
Cancer. 2012; 118: 1313-1322- Merchant T.E.
- Wang M.H.
- Haida T.
- et al.
Medulloblastoma: long-term results for patients treated with definitive radiation therapy during the computed tomography era.
Int J Radiat Oncol Biol Phys. 1996; 36: 29-35- Yock T.I.
- Yeap B.Y.
- Ebb D.H.
- et al.
Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study.
Lancet Oncol. 2016; 17 (): 287-298- Brown A.P.
- Barney C.L.
- Grosshans D.R.
- et al.
Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma.
Int J Radiat Oncol Biol Phys. 2013; 86: 277-284- Das P.
- Soni P.
- Jones J.
- et al.
Descriptive epidemiology of chordomas in the United States.
J Neurooncol. 2020; 148: 173-178- Young V.A.
- Curtis K.M.
- Temple H.T.
- et al.
Characteristics and patterns of metastatic disease from chordoma.
Sarcoma. 2015; 2015: 517657- George B.
- Bresson D.
- Herman P.
- et al.
Chordomas: a review.
Neurosurg Clin N Am. 2015; 26: 437-452- Stacchiotti S.
- Sommer J.
- Chordoma Global Consensus Group
Building a global consensus approach to chordoma: a position paper from the medical and patient community.
Lancet Oncol. 2015; 16: e71-e83Skull base chordoma treated with proton therapy: a systematic review.
Surg Neurol Int. 2019; 10: 96- DeLaney T.F.
- Liebsch N.J.
- Pedlow F.X.
- et al.
Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas.
Int J Radiat Oncol Biol Phys. 2009; 74: 732-739- Palm R.F.
- Oliver D.E.
- Yang G.Q.
- et al.
The role of dose escalation and proton therapy in perioperative or definitive treatment of chondrosarcoma and chordoma: An analysis of the National Cancer Data Base.
Cancer. 2019; 125: 642-651Vestibular Schwannoma.
in: Møller A.R. Langguth B. De Ridder D. Textbook of tinnitus. Springer,
2011: 681-686- Yang I.
- Sughrue M.E.
- Han S.J.
- et al.
A comprehensive analysis of hearing preservation after radiosurgery for vestibular schwannoma: Clinical article.
J Neurosurg. 2010; 112: 851-859- Régis J.
- Roche P.H.
- Delsanti C.
- et al.
Modern management of vestibular schwannomas.
Prog Neurol Surg. 2007; 20: 129-141- Barnes C.J.
- Bush D.A.
- Grove R.I.
- et al.
Fractionated proton beam therapy for acoustic neuromas: tumor control and hearing preservation.
Int J Part Ther. 2018; 4: 28-36- Vernimmen F.J.A.I.
- Mohamed Z.
- Slabbert J.P.
- et al.
Long-term results of stereotactic proton beam radiotherapy for acoustic neuromas.
Radiother Oncol. 2009; 90: 208-212- Zhu S.
- Rotondo R.
- Mendenhall W.M.
- et al.
Long-term outcomes of fractionated stereotactic proton therapy for vestibular schwannoma: a case series.
Int J Part Ther. 2018; 4: 37-46- Koetsier K.S.
- Hensen E.F.
- Wiggenraad R.
- et al.
Clinical outcomes and toxicity of proton radiotherapy for vestibular schwannomas: a systematic review.
J Radiat Oncol. 2019; 8: 357-368- Sheehan J.P.
- Kano H.
- Xu Z.
- et al.
Gamma Knife radiosurgery for facial nerve schwannomas: a multicenter study.
J Neurosurg. 2015; 123: 387-394- Beck-Peccoz P.
- Brucker-Davis F.
- Persani L.
- et al.
Thyrotropin-secreting Pituitary Tumors Endocr Rev. 1996; 17: 610-638- Kreutzer J.
- Vance M.L.
- Lopes M.B.S.
- et al.
Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria.
J Clin Endocrinol Metab. 2001; 86: 4072-4077- Becker G.
- Kocher M.
- Kortmann R.D.
- et al.
Radiation therapy in the multimodal treatment approach of pituitary adenoma.
Strahlenther Onkol. 2002; 178: 173-186Radiation therapy in the management of pituitary adenomas.
J Clin Endocrinol Metab. 2011; 96: 1992-2003- Bolsi A.
- Fogliata A.
- Cozzi L.
Radiotherapy of small intracranial tumours with different advanced techniques using photon and proton beams: A treatment planning study.
Radiother Oncol. 2003; 68: 1-14- Winkfield K.M.
- Niemierko A.
- Bussiere M.R.
- et al.
Modeling intracranial second tumor risk and estimates of clinical toxicity with various radiation therapy techniques for patients with pituitary adenoma.
Technol Cancer Res Treat. 2011; 10: 243-251- Boehling N.S.
- Grosshans D.R.
- Bluett J.B.
- et al.
Dosimetric comparison of three-dimensional conformal proton radiotherapy, intensity-modulated proton therapy, and intensity-modulated radiotherapy for treatment of pediatric craniopharyngiomas.
Int J Radiat Oncol Biol Phys. 2012; 82: 643-652Proton-beam therapy of pituitary disease: bragg peak proton treatment for pituitary-related conditions.
Proc R Soc Med. 1974; 67: 32-33- Petit J.H.
- Biller B.M.K.
- Yock T.I.
- et al.
Proton stereotactic radiotherapy for persistent adrenocorticotropin-producing adenomas.
J Clin Endocrinol Metab. 2008; 93: 393-399- Petit J.H.
- Biller B.M.K.
- Coen J.J.
- et al.
Proton stereotactic radiosurgery in management of persistent acromegaly.
Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2007; 13: 726-734- Wattson D.A.
- Tanguturi S.K.
- Spiegel D.Y.
- et al.
Outcomes of proton therapy for patients with functional pituitary adenomas.
Int J Radiat Oncol Biol Phys. 2014; 90: 532-539- Ronson B.B.
- Schulte R.W.
- Han K.P.
- et al.
Fractionated proton beam irradiation of pituitary adenomas.
Int J Radiat Oncol Biol Phys. 2006; 64: 425-434- Aghi M.K.
- Petit J.
- Chapman P.
- et al.
Management of recurrent and refractory Cushing’s disease with reoperation and/or proton beam radiosurgery.
Clin Neurosurg. 2008; 55: 141-144- Kjellberg R.N.
- Shintani A.
- Fanzt A.G.
- et al.
Proton beam therapy in acromegaly.
N Engl J Med. 1968; 278: 669-695- Levin W.P.
- Kooy H.
- Loeffler J.S.
- et al.
Proton beam therapy.
Br J Cancer. 2005; 93: 849-854